Researchers developed and validated a diagnostic prediction model to distinguish between juvenile idiopathic arthritis and chronic musculoskeletal pain syndrome.
Researchers sought to determine the outcomes among pediatric patients with rheumatic disease and COVID-19.
Significantly more patients with JIA stopped taking their medications over a period of 18 vs 8 years after disease onset.
The American College of Rheumatology (ACR) developed updated guidelines for the pharmacologic management of juvenile idiopathic arthritis, with a focus on treatment of oligoarthritis, temporomandibular joint arthritis, and systemic JIA.
Randy Cron, MD, PhD, Mara Becker, MD, MSCE, and Robert Fuhlbrigge, MD, PhD, provide a deeper insight into precision medicine-based approaches in juvenile idiopathic arthritis.
This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of polyarticular juvenile idiopathic arthritis.
The aim of the systematic review was to collect information currently available on health care costs associated with JIA after the introduction of biologic therapies.
In this episode, Mara Becker, MD, highlights the importance of collaboration between ophthalmology and rheumatology for the management of adults with juvenile idiopathic arthritis-associated uveitis.
Researchers studied the association between 25-(OH)D levels and incidence of juvenile idiopathic arthritis, using Mendelian randomization.
In a double-blind, withdrawal, phase 3 trial, researchers assessed the efficacy and safety of tofacitinib vs placebo among patients with polyarticular-course juvenile idiopathic arthritis.
